High materiality7/10
Teva Pharma (TEVA) PT Raised to $48 at UBS
Why it may matterVerify against the original reporting
Positive catalyst from UBS target raise; suggests potential upside
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS raises TEVA price target to $48. Posted price: $36.62. Analyst: Ashwani Verma. PriceChangeSinceSignal: -0.71. This implies an improved near-term upside expectation despite a small recent price dip.
- UBS raises TEVA PT to $48; price $36.62; Ashwani Verma
Key facts
- 01
Target: $48
- 02
Posted price: $36.62
- 03
Analyst firm: UBS
- 04
Analyst: Ashwani Verma
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.